Stock listing

ASX:COV CLEO Diagnostics Ltd Share Price

Home listing (ASX) of CLEO Diagnostics Ltd

Follow CLEO Diagnostics Ltd into a list and get an email when it puts out news.

Share price · ASX:COV

$0.26 AUD 0.00 (0.0%)

Close on Nov 20, 2026

Past year -52.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.245 – $0.26 AUDNov 20, 2026
Volume
242,953 sharesNov 20, 2026
Market cap
$37.02M AUDAt the close on Nov 20, 2026 · price × 142.4M shares outstanding
52-week range
$0.245 – $0.90 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$31,514 AUDMedian day 58,806 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
CLEO Diagnostics Ltd logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:COV · Home$0.26 AUD0.00 (0.0%)242,953$0.25$0.26$0.245$0.26Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:COV · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.260.000.0%$0.25$0.26$0.245242,953
$0.26-0.015-5.5%$0.275$0.275$0.2623,869
$0.275+0.005+1.9%$0.275$0.275$0.27510,004
$0.270.000.0%$0.27$0.27$0.27352
$0.27-0.02-6.9%$0.29$0.29$0.27154,653
$0.29+0.005+1.8%$0.285$0.29$0.28558,791
$0.285-0.015-5.0%$0.29$0.29$0.2837,015
$0.30+0.01+3.4%$0.30$0.30$0.30978
$0.29+0.02+7.4%$0.28$0.29$0.2830,527
$0.27-0.01-3.6%$0.28$0.28$0.272,493
$0.28+0.005+1.8%$0.285$0.285$0.27573,627
$0.275-0.02-6.8%$0.29$0.29$0.26190,183
$0.2950.000.0%$0.295$0.295$0.29545,025
$0.2950.000.0%$0.295$0.295$0.29596
$0.295-0.005-1.7%$0.30$0.30$0.295140,150
$0.30+0.005+1.7%$0.295$0.30$0.29511,569
$0.2950.000.0%$0.295$0.30$0.29558,780
$0.295-0.01-3.3%$0.305$0.305$0.29547,536
$0.305-0.015-4.7%$0.305$0.305$0.29385,936
$0.32+0.015+4.9%$0.312$0.32$0.3122,123
$0.305-0.01-3.2%$0.305$0.315$0.3068,808
$0.315+0.01+3.3%$0.345$0.355$0.305237,701
$0.3050.000.0%$0.305$0.305$0.3056,938
$0.305-0.005-1.6%$0.32$0.32$0.30106,387
$0.31-0.01-3.1%$0.31$0.31$0.312,000
$0.32-0.01-3.0%$0.33$0.33$0.295171,047
$0.33-0.015-4.3%$0.34$0.34$0.31578,853
$0.345-0.005-1.4%$0.35$0.36$0.33204,569
$0.35+0.035+11.1%$0.32$0.35$0.31128,274
$0.315+0.005+1.6%$0.315$0.32$0.31558,821
$0.31-0.01-3.1%$0.315$0.315$0.3125,303
$0.32-0.03-8.6%$0.35$0.35$0.326,611
$0.350.000.0%$0.34$0.35$0.341,500
$0.35+0.005+1.4%$0.335$0.35$0.33525,547
$0.345+0.025+7.8%$0.32$0.345$0.315202,365
$0.32+0.035+12.3%$0.305$0.32$0.295123,565
$0.285+0.005+1.8%$0.285$0.30$0.28577,261
$0.28-0.01-3.4%$0.29$0.29$0.2848,985
$0.29-0.005-1.7%$0.295$0.295$0.2891,791
$0.2950.000.0%$0.295$0.295$0.27570,452
$0.295-0.01-3.3%$0.305$0.305$0.29809,172
$0.305-0.025-7.6%$0.32$0.32$0.295133,221
$0.33+0.03+10.0%$0.31$0.335$0.31224,917
$0.30-0.01-3.2%$0.31$0.315$0.295189,247
$0.31-0.015-4.6%$0.32$0.32$0.3150,203
$0.325+0.01+3.2%$0.315$0.325$0.293197,552
$0.315+0.005+1.6%$0.32$0.325$0.31517,760
$0.31-0.025-7.5%$0.34$0.345$0.31130,740
$0.335+0.02+6.3%$0.34$0.34$0.33527,580
$0.315-0.025-7.4%$0.325$0.325$0.315172,265
$0.340.000.0%$0.33$0.355$0.325154,485
$0.34-0.01-2.9%$0.34$0.34$0.3394,543
$0.35-0.005-1.4%$0.355$0.355$0.3554,100
$0.355-0.03-7.8%$0.37$0.37$0.35533,835
$0.385-0.015-3.8%$0.41$0.42$0.36126,308
$0.40+0.05+14.3%$0.395$0.40$0.38550,247
$0.350.000.0%$0.35$0.35$0.350
$0.35+0.005+1.4%$0.345$0.36$0.3462,943
$0.3450.000.0%$0.345$0.345$0.34527,934
$0.345+0.005+1.5%$0.34$0.345$0.325204,681
$0.34-0.02-5.6%$0.335$0.35$0.33512,277
$0.36+0.005+1.4%$0.345$0.36$0.3457,676
$0.355+0.015+4.4%$0.345$0.355$0.33557,510
$0.34+0.023+7.1%$0.325$0.34$0.325132,816
$0.318-0.013-3.8%$0.32$0.323$0.31539,565
$0.330.000.0%$0.34$0.34$0.33135,142
Ticker
ASX:COV
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
ASX
Currency
AUD

What changed lately

Latest news

All CLEO Diagnostics Ltd news

CLEO Diagnostics Ltd on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
32 in the last 12 months · 60 in all · newest Nov 11, 2026 · oldest 2023
Decks
2 decks · latest Jun 12, 2025

Where CLEO Diagnostics Ltd is listed

ListingExchangeCountryCurrency
ASX:COV · Home listing · This pageASXAustraliaAUD
OTC:CLDGFOTCUnited StatesUSD

Valuation

Price/book 7.4× against a median of 1.0×: the highest of 11 Diagnostics & research services companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$30.80M AUD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
7.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
CLEO Diagnostics Ltd · ASX:COVUS$24.57MUS$20.44Mn/an/an/a7.4×n/a0.0×n/a
Bioptic Inc. · TPEX:6850US$26.11MUS$22.55Mn/an/an/a2.0×n/a0.2×n/a
genOway SA · EURONEXT:ALGENUS$25.87MUS$38.95M25.4×1.7×8.7×1.1×4.4%0.7×n/a
Orientbio, Inc. · KRX:002630US$25.03M−US$3.27M14.6×−0.1×−0.8×0.5×8.1%0.0×n/a
Clever Culture Systems Limited · ASX:CC5US$24.62MUS$25.47Mn/a8.3×n/a4.9×−48.4%0.4×n/a
Genesystem Co., Ltd. · KRX:363250US$24.54MUS$22.35Mn/a29.8×n/a2.8×n/a0.2×n/a
C&R Research Inc. · KRX:359090US$23.87MUS$12.44M19.3×0.3×23.4×0.7×2.6%0.0×n/a
HLB Panagene Co. Ltd. · KRX:046210US$23.55MUS$6.15Mn/a0.6×n/a0.4×−22.3%0.0×n/a
IMBdx, Inc. · KRX:461030US$23.49MUS$10.14Mn/a2.4×n/a1.4×−135.5%0.0×n/a
QuantaMatrix, Inc. · KRX:317690US$23.36MUS$881,618n/a0.4×n/a1.0×−567.5%0.0×n/a
Genolution Inc. · KRX:225220US$23.33MUS$3.40Mn/a0.5×n/a0.5×−46.5%0.0×n/a
Median of the othersUS$24.21MUS$11.29M19.3×0.6×8.7×1.0×−34.4%0.0×

Team and board

Officers

OfficerRole
Richard AllmanChief Executive Officer and Executive Director
Pauline MoffattCompany Secretary
Andrew StephensChief Scientific Officer and Executive Director

Board

DirectorRole
Adrien WingNon-Executive Chair
Andrew StephensChief Scientific Officer and Executive Director
Lucinda NolanNon-Executive Director
Richard AllmanChief Executive Officer and Executive Director
Tom JoblingLead Medical Advisor and Non-Executive Director

Events

QuarterResultsShare move
Q4 2025Aug 26, 2025−0.7%
Q2 2025Feb 27, 2025−6.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (June 2025)Investor deck22 slidesJun 12, 2025
Investor Presentation (February 2024)Investor deck21 slidesFeb 20, 2024

Open Decks

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022
Revenue1.18M600.1K110.1K0
Selling, general and administrative2.49M2.14M1.58M1.39M
Operating income-7.89M-3.90M-3.61M-1.58M-23.3K
Depreciation and amortization64.4K60.5K59.2K43.8K
EBITDA-7.82M-3.84M-3.55M-1.53M
Interest expense26.5K110.8K
Income before tax-5.94M-4.00M-3.76M-1.73M-43.9K
Net income-5.94M-4.00M-3.76M-1.73M-43.9K
Earnings per share, basic-0.04-0.03-0.03-0.01-0.00

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022
Cash and equivalents6.22M747.0K7.32M239.8K42.8K
Receivables70.6K57.4K31.9K860
Current assets6.34M6.55M9.44M580.2K43.6K
Property, plant and equipment32.6K31.9K38.1K
Total assets6.68M6.94M9.88M1.08M243.6K
Accounts payable1.29M870.8K439.9K417.4K
Current liabilities1.67M1.10M486.2K2.02M285.9K
Total liabilities1.67M1.10M486.2K2.02M285.9K
Shareholders' equity5.01M5.83M9.39M-943.4K-42.3K
Shares outstanding137.1M128.5M128.5M128.5M128.5M

Cash flow

LineFY2026FY2025FY2024FY2023
Cash from operations-2.90M-2.03M-684.5K
Capital spending-9.42K-11.1K-3.05K-340.2K
Free cash flow-4.95M-2.91M-2.03M-1.02M
Cash from investing-11.1K-3.05K-340.2K
Cash from financing4.71M011.2M1.22M
Share buybacks-373.2K012.0M0
Change in cash-236.5K-2.91M9.13M197.0K

Open Financials

Filings

FilingDateTypeFiled with
CLEO Advances Toward Clinical ValidationNov 11, 2026Operations updateASX
Quarterly activities and cashflow reportOct 30, 2026Quarterly reportASX
Quarterly activities and cashflow reportOct 30, 2026Quarterly reportASX
CLEO Screening Test Meets Rigorous Performance TargetsOct 20, 2026Operations updateASX
CLEO Screening Test Meets Rigorous Performance TargetsOct 20, 2026Operations updateASX
CLEO Commences Analytical Validation Ahead of FDA SubmissionOct 12, 2026Operations updateASX
Cleo Files Patents for its Ovarian Cancer Screening TestSep 29, 2026Other filingsASX
CLEO Commences Ovarian Cancer Screening Test DevelopmentSep 23, 2026Operations updateASX
Letter to ShareholdersSep 16, 2026Meeting noticeASX
Notice of Annual General Meeting/Proxy FormSep 16, 2026Meeting noticeASX
All 60 filings
FilingDateTypeFiled with
Notice Required Under ASX Listing Rule 3.13.1Sep 10, 2026Other filingsASX
CLIA Certified Lab selected - Pivotal US Clinical ValidationSep 9, 2026Operations updateASX
CLEO Receives First Batch of Commercial Test KitsSep 2, 2026Operations updateASX
Change of Director's Interest Notice x 4Aug 24, 2026Ownership change noticeASX
Cleansing NoticeAug 24, 2026FinancingASX
Application for quotation of securities - COVAug 24, 2026FinancingASX
Notification of cessation of securities - COVAug 24, 2026FinancingASX
Change in Director's Interest NoticeAug 21, 2026Ownership change noticeASX
Appendix 4E and 2026 Annual ReportAug 20, 2026Annual reportASX
Appendix 4G and Corporate Governance StatementAug 20, 2026Other filingsASX
Quarterly activities and cashflow reportJul 28, 2026Quarterly reportASX
CLEO Enters Analytical Validation PhaseJul 12, 2026Operations updateASX
CLEO Establishes U.S. Reimbursement PathwayMay 19, 2026Operations updateASX
CLEO Commences Kit Manufacturing Ahead of FDA SubmissionApr 27, 2026Operations updateASX
Sample Collection Completion for Pivotal US Clinical TrialMar 30, 2026Operations updateASX
CLEO Optimises Biomarker Panel Ahead of FDA SubmissionMar 22, 2026Operations updateASX
Appendix 4D and Half Yearly AccountsFeb 25, 2026Interim reportASX
CLEO Confirms Next-Gen Platform for Ovarian Cancer TestFeb 17, 2026Operations updateASX
Quarterly activities and cashflow reportJan 28, 2026Quarterly reportASX
CLEO Raises $5m to Support U.S. Market LaunchDec 17, 2025FinancingASX
Trading HaltDec 16, 2025Trading halt or suspensionASX
Cleo Strengthens Cash Position with $1.7m R&D Tax RefundNov 25, 2025FinancingASX
CLEO Appoints First Key Opinion Leader to Support US MarketNov 18, 2025Operations updateASX
CLEO Significantly Expands Addressable MarketNov 5, 2025Operations updateASX
CLEO Successfully Completes Stage 1 MDSAP AuditOct 29, 2025Operations updateASX
Cleo Receives Positive FDA FeedbackSep 14, 2025Operations updateASX
Appendix 4E and 2025 Annual ReportAug 26, 2025Annual reportASX
COV Commences Health Economic Study-Support US Market EntryAug 17, 2025Operations updateASX
CLEO Strengthens FDA Submission - Access to US BiobankJun 25, 2025Operations updateASX
Corporate PresentationJun 11, 2025Other filingsASX
Cleo Advances with Completion of Alpha TestingMay 12, 2025Operations updateASX
CLEO to Fast Track Development of Ovarian Cancer TestApr 27, 2025Operations updateASX
CLEO Receives A$845k Research and Development Tax IncentiveApr 24, 2025ResultsASX
CLEO Delivers Commercial Development MilestoneMar 17, 2025Operations updateASX
Price Query ResponseFeb 7, 2025Explanation requestASX
CLEO Further Expands Ovarian Cancer Trial with Siles HealthDec 9, 2024Operations updateASX
The Royal Women's Hospital Joins CLEO Ovarian Cancer TrialNov 26, 2024Other filingsASX
Cleo Commences U.S. Clinical TrialsSep 5, 2024Other filingsASX
Appendix 4E and 2024 Annual ReportAug 27, 2024Annual reportASX
CLEO Selects U.S. Clinical Trial SitesJul 30, 2024Operations updateASX
Cleo Commences US Regulatory Process with FDAJun 25, 2024Operations updateASX
COV Ovarian Cancer Blood Test Outperforms Clinical BenchmarkMay 28, 2024Other filingsASX
COV Appoints CRO to Manage US Ovarian Cancer Clinical TrialsApr 10, 2024Other filingsASX
CLEO Appoints Partner to Commence U.S. Market Access ProgramApr 2, 2024Operations updateASX
Peer-Review Supports CLEOs Ovarian Cancer Detection TechMar 24, 2024Operations updateASX
Cleo Completes Design TransferFeb 11, 2024Operations updateASX
Completion of First Triage Test Clinical Validation StudyNov 5, 2023Other filingsASX
Pause in TradingNov 2, 2023Trading halt or suspensionASX
Cleo Delivers Early Progress on Development ProgramOct 8, 2023Operations updateASX
Appendix 4E and Preliminary Financial ReportAug 31, 2023ResultsASX

Open Filings

Cap table

Built by 6ix from CLEO Diagnostics Ltd’s releases

Common shares
142,383,746
Fully diluted
142,383,746

Fully diluted

LineShares
Common shares142,383,746

Share count over time

CountShares
Nov 22, 2026142,383,746

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Adrien WingNon-Executive Chair · Since at least Oct 12, 2026
Andrew StephensChief Scientific Officer and Executive Director · Since at least Nov 5, 2026
Lucinda NolanNon-Executive Director · Since at least Nov 5, 2026
Pauline MoffattCompany Secretary · Since at least Nov 5, 2026
Richard AllmanChief Executive Officer and Executive Director · Since at least Oct 12, 2026
Tom JoblingLead Medical Advisor and Non-Executive Director · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about CLEO Diagnostics Ltd.